Physician profile
Amber L Simonson
NPI 1386689156
$6,190.70
in general payments reported to CMS, 2019-2025
12 companies · $2,363 in 2025
The $2,363 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,099 · 2020: $107 · 2021: $1,088 · 2022: $491 · 2023: $537 · 2024: $506 · 2025: $2,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,764 · Travel and Lodging: $1,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,764.03 |
| Travel and Lodging | $1,642.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $2,136.66 | 2019-2025 | Misight Contact Lens, Myday Contact Lens |
| Alcon Vision LLC | $1,690.40 | 2019-2024 | Total30, Precision 1, Dailies Total1 |
| Johnson & Johnson Vision Care, INC. | $738.23 | 2019-2023 | Acuvue |
| Bausch & Lomb Americas INC. | $722.96 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Novartis Pharmaceuticals Corporation | $295.22 | 2019-2022 | |
| Sight Sciences, INC. | $224.99 | 2021-2025 | Tearcare System |
| Sun Pharmaceutical Industries INC. | $140.92 | 2019-2021 | |
| Shire North American Group INC | $128.31 | 2019 | |
| Allergan, INC. | $70.29 | 2021 | |
| Kala Pharmaceuticals, INC. | $16.80 | 2021 | |
| Biotissue Holdings INC. | $14.71 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $11.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Simonson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.